Seaport Therapeutics priced its initial public offering this week at $201 million, offering 11.8 million shares at $17 per share—the midpoint of its $16-$18 range. The Cambridge-based company becomes the first standalone neuropsychiatric platform to reach public markets since last June, when CNS-focused biotechs drew zero institutional appetite.

The company's lead asset, SPN-830, targets major depressive disorder with a proprietary oral formulation of galnopam, a GABA-A modulator. Phase 2 data showed efficacy at day 14 in 72 patients, with onset signals at day 3. Second candidate SPN-817 addresses post-partum depression with a twice-daily oral analog of brexanolone, the Sage Therapeutics IV therapy that carries a $34,000 price tag and requires 60-hour hospital infusion. Seaport's version completed Phase 1 safety trials in 48 subjects last October.

The pricing matters because neuropsychiatric platforms have been shut out of capital formation since early 2023, when three consecutive CNS-focused biotechs withdrew IPO attempts after failing to secure anchor orders. Allocators soured on the category following Axsome Therapeutics' 47% equity collapse in March 2023 and Sage's $2.1 billion market-cap evaporation through 2022-2023 despite FDA approvals. The sector's challenge: commercial execution on complex psychiatry scripts has historically lagged Phase 3 optimism by 18-24 months, creating a credibility gap that made IPO syndication impossible.

Seaport's successful pricing suggests a narrow reopening. The company raised $150 million in Series B financing last April led by RA Capital and Nextech, giving it $340 million pro-forma cash post-IPO. That runway funds two Phase 3 trials for SPN-830 starting Q2 2025, each enrolling 300+ patients across 40-50 sites. The company expects topline readouts in Q4 2026. Underwriters include Jefferies, Leerink Partners, and Guggenheim—the same syndicate that priced Neumora Therapeutics' $250 million IPO in April 2023, which currently trades 38% below issue.

Allocators should track three follow-on signals. First, whether Seaport holds $17 through the first 30 days of trading, which would validate the pricing as institutional rather than forced. Second, if two other neuropsych platforms—one NMDA-focused, one psychedelic-adjacent—file S-1 amendments in the next 45 days, suggesting syndicate appetite extends beyond Seaport. Third, whether RA Capital, which holds 22% post-IPO, adds to its position in the open market before the 180-day lockup expires, a signal it views $17 as below intrinsic.

Seaport's market debut arrives as the broader biotech IPO window shows $4.8 billion in proceeds year-to-date across 19 offerings, compared to $2.1 billion through the same period last year. The S&P Biotechnology Select Index has gained 8.2% since January 1, with CNS-focused names lagging at 3.1%. Seaport's Phase 3 initiation is scheduled for May 15.